Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04853758

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04853758
Other papers using this trial's data
  • Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial Journal of the American College of Cardiology, 2026-03-17 DOI, PubMed 41396086

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04853758. Randomized; triple masking; primary purpose treatment. Start 2021-05-06 (actual); primary completion 2024-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
Acronym
ANSWER-HF
Condition
Chagas Cardiomyopathy
Intervention (Drug)
Sacubitril / Valsartan Oral Tablet [Entresto]
Intervention (Drug)
Enalapril
Lead sponsor
University of Sao Paulo General Hospital (class: other)
Collaborator
InCor Heart Institute (class: other)

Record details

Record id
cardio:ct-nct04853758
Content hash
c1c780a87c17d03ef66d10f735d1e37abc0c9c1ce02d8dc26fe37c1f33f2e2bf